All In Biotech

Drug Trial Radar · NCT05299073

A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva

A Randomised, Double-blind, Three-arm, Single-dose, Parallel Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Profile of MB09 (Denosumab Biosimilar) and EU/US-sourced Xgeva® in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 257 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

257

Actual

Start

Mar 1, 2022

Primary completion

Mar 18, 2023

Study completion Mar 18, 2023

Sponsor

Lead sponsor
mAbxience Research S.L.Industry
Sponsor type
Industry
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 28 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the PK, PD, safety and immunogenicity profile of MB09 with EU/US-Xgeva® in healthy male subjects. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Pharmacodynamics, safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.

Conditions

  • Healthy Volunteers

Interventions

  • MB09Drug

    Single dose of 35mg SC administered

  • US-sourced XgevaDrug

    Single dose of 35mg SC administered

  • EU-sourced XgevaDrug

    Single dose of 35mg SC administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-lastTime frame: Day 1 to Day 253
  2. CmaxTime frame: Day 1 to Day 253

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Biokinetica - Early Phase Institute

    Józefów, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.